Jazz Pharmaceuticals swings to Q3 net loss of $483.4 million
JAZZ•Jazz Pharmaceuticals reported a third-quarter 2026 net loss of $483.4 million, including $754 million in Actio-related acquired IPR&D expense, while revenue rose 10% to $1.24 billion. The company raised its full-year revenue guidance to $4.78 billion–$4.85 billion.
1. Quarterly results and guidance
Jazz Pharmaceuticals swung to a third-quarter 2026 net loss of $483.4 million, including $754 million in Actio-related acquired IPR&D expense. Total revenues rose 10% year over year to $1.24 billion, and the company increased its full-year 2026 revenue guidance to $4.78 billion–$4.85 billion.
2. Ziihera approval and launch
Ziihera received FDA approval and launched for first-line treatment of adults with HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma.
